(Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36274 Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q INTRA-CELLULAR THERAPIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4 ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jess ...

or Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36274 INTRA-CELLULAR THERAPIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-474285 ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jessic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(b) of the Act: | | Trading | Name of each exchange | | --- | --- | --- | | Title of each cla ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Juan Sanchez – Vice President-Corporate Communications and Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Executive Vice President and Chief Commercial Officer Larry Hineline – Senior Vice President and Chief Financial Officer Conference Call Participants Jessica Fye – JPMorgan Brian Abrahams – RBC Capital Markets Andrew Tsai – Jefferies Mike DiFi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 New York, New York 10016 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (646) 440-9333 Securities registered pursuant to ...

Corporate Presentation February 2022 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our plans to commercialize CAPLYTA f ...

Corporate Presentation January 2022 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our plans to commercialize CAPLYTA fo ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Larry Hineline - Senior Vice President of Finance and Chief Financial Officer Suresh Durgam - Senior Vice President and Chief Medical Officer Conference Call Participants Br ...